Immix Biopharma Investor Presentation Deck
BCMA Bispecific Antibodies (Tecvayli, Elrexfio) Are Currently Being Investigated As
An Outpatient Therapy
01 Outpatient
Tecvayli "safe
and feasible"
02 Administration
of Tecvayli will
"not be the same
as in MajesTEC-1"
03 Clinical trials
underway to test
outpatient BCMA
BsAbs
Asya Nina Varshavsky-Yanovsky, MD, PhD
Department of Bone Marrow Transplant
and Cellular Therapies
• Fox Chase-Temple University Hospital
Jeffrey Matous, MD
• Colorado Blood Cancer Institute
• Plasma Cell Diseases Group
Trial #
Drug
Phase
azon
# pts
Start date
LOT
Primary endpoint
"We have treated over 20 patients with our outpatient [Teclistamab dosing] program so far [in r/r
MM] ... in conclusion outpatient Teclistamab, step up administration model with close monitoring
is safe and feasible in heavily pretreated patients with rrMM allows significant reduction of patient
stay which results in healthcare savings and an improvement of patient experience"
Aug 4, 2023
"teclistamab has been approved
based on the MajesTEC-1 study,
where it was given a certain way.
I'm convinced that's not how we'll
be using teclistamab in the future"
May 24, 2023
AJMC
NCT05972135
Tecvayli (Teclistamab)
2
50
9/30/2023
Received 4 or more prior therapies
Incidence of CRS
Yan Ji, MD
• HealthPartners Cancer Center
at Regions Hospital
**EHA
PANDIRAL
HEMATOLOGY
●●●
IMMIX
S BIOPHARMA
NCT06015542
"We learned how to give patients
daratumumab [Darzalex]. Initially,
there were a lot of infusion reactions.
Now everybody feels very comfortable
and we give it to patients all the time"
May 10, 2023
Elrexfio (Elranatamab)
EHA2023
JUNE 8-16/PMANKFURT & VIRTUAL
Targeted
Oncology
2
20
1/1/2024
21 proteasome inhibitor, IMID and anti CD-38 mAb
Safety
55View entire presentation